80 results about "Apoptosis induction" patented technology

The invention relates to a stem cell bioactive nano-vesicle with efficient inflammation regulation and tissue repair effects, the average particle size of the nano-vesicle is 100-350nm, the polydispersity index (PDI) is 0.05-0.40, and the expression rate of phosphatidylserine (PS) on the surface of the nano-vesicle is greater than 40%. According to the preparation method, stem cells are subjected to apoptosis induction, and then a programmed serial extrusion process is adopted to prepare the nano-vesicles. The nano vesicles are moderate in particle size, uniform in distribution and high in production efficiency, the preparation process is easy to operate, the quality is stable and controllable, and the nano vesicles have excellent technical effects in the aspects of repair and regeneration of inflammation injury type tissues and organs.

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine drug resistance and application of the pharmaceutical composition, and belongs to the technical field of biological medicine. The composition comprises a generic FGFR inhibitor delatinib and gemcitabine, the concentration of the delatinib is 25 to 50 mg / kg, and the concentration of the gemcitabine is 20 to 30 mg / kg. By inhibiting an FGFR2 / FGFR3 signal channel and reducing the expression of FGFR protein in drug-resistant cells, the chemosensitivity of gemcitabine is synergistically enhanced, the apoptosis induction rate is increased by more than two times, and the synergic index (CI) is less than 1. In-vitro and nude mouse transplantation tumor experiments prove that the composition can significantly inhibit the proliferation of gemcitabine drug-resistant pancreatic cancer cells. The Gemcitabine drug-resistant pancreatic cancer drug can be used for preparing a drug for treating Gemcitabine drug-resistant pancreatic cancer with high FGFR3 expression, patients are screened through immunohistochemistry or gene sequencing, intravenous injection or oral administration is adopted, dosage forms comprise freeze-dried powder injection, capsules or tablets, and a new strategy is provided for pancreatic cancer drug-resistant treatment.

The invention relates to an application of galuteolin-sensitized cis-platinum in preparation of a medicine for treating esophageal squamous cell carcinoma. It is found that the galuteolin can block the progress of esophageal squamous carcinoma cells in multiple links including apoptosis induction, growth and invasion inhibition and the like, the galuteolin can also significantly enhance inhibition of cis-platinum on lymphatic metastasis of esophageal squamous carcinoma cells in a mouse model, and the galuteolin and the cis-platinum have a significant synergistic effect.

The invention discloses a pharmaceutical composition and a medicine for treating acute myelogenous leukemia in cooperation with vinca. The pharmaceutical composition is prepared from AGX51, vinca and a proper amount of solvent. In the pharmaceutical composition, the concentration ratio of the AGX51 to the vinca is 200: (1-40); the AGX51 in the pharmaceutical composition can improve the proliferation inhibition capability of a single Venoclara drug by 2.2 times or more; the AGX51 in the pharmaceutical composition can improve the apoptosis induction capability of a single drug of Venoclara by 3.6 times or more.

The invention particularly relates to a curcumin delivery system based on small extracellular vesicles, a preparation method and application. Curcumin has the defects of poor water solubility, poor chemical stability and insufficient targeting, in order to improve the bioavailability of curcumin, the curcumin delivery system based on small extracellular vesicles provided by the invention adopts RGD peptide surface modified sEVs as a carrier to coat curcumin, and saponin is used for assisting ultrasonic drug loading, so that the drug loading rate of curcumin is improved. According to verification of the invention, the delivery system can effectively improve the in-vitro release performance of the curcumin preparation and realize controlled release and slow release. Meanwhile, the delivery system effectively improves apoptosis induction of curcumin to glioma cells, the blood-brain barrier penetrating capacity of the curcumin delivery system is improved, and the treatment effect on brain glioma is expected to be improved.

The disclosure provides synthetic cytotoxic cells, comprising a hydrogel microsphere and a TNF-related apoptosis-inducing ligand (TRAIL), or active fragment thereof. In aspects, the TRAIL or active fragment thereof is attached to the surface of the hydrogel microsphere. The disclosure further provides methods of preparing the synthetic cytotoxic cells and methods of use thereof in the treatment of cancer.

The invention relates to application of chrysin-sensitized cis-platinum in treatment of esophageal squamous cell carcinoma. It is found that chrysin can sensitize the growth inhibition effect, invasion inhibition effect and apoptosis induction effect of cis-platinum-mediated esophageal squamous carcinoma cells in a dose-dependent manner, and can effectively enhance the growth inhibition and apoptosis promotion effect of cis-platinum-mediated tumors to inhibit the increase of the tumor volume. The inhibition of cis-platinum on lymphatic metastasis of esophageal squamous carcinoma cells is remarkably enhanced, and a synergistic anti-cancer effect is generated through combination of cis-platinum and cis-platinum.

The invention provides application of 3-indoleacetic acid combined with temozolomide in resisting brain glioma, and belongs to the field of biological medicine. Wherein the 3-indoleacetic acid can significantly enhance the inhibition effect of temozolomide on brain glioma cells in a short period and a long period, and can significantly enhance the apoptosis induction effect of temozolomide on the brain glioma cells, and after the 3-indoleacetic acid and temozolomide are applied to a brain glioma animal model, the 3-indoleacetic acid and temozolomide are combined, so that the inhibition effect of temozolomide on brain glioma cells is obviously improved. The 3-indoleacetic acid and temozolomide can obviously inhibit the development of brain glioma and relieve weight loss caused by temozolomide administration, so that the 3-indoleacetic acid and temozolomide have the potential of being developed into the anti-brain glioma medicine.

The present application provides antigen-binding proteins (e.g., antibodies such as single-domain antibodies) that specifically bind TNF-related apoptosis-inducing ligand receptor 2 (TRA5LR2). The application also provides fusion proteins and conjugates comprising the antigen-binding proteins, polynucleotides and recombinant vectors encoding the antigen-binding proteins, as well as host cellsand methods for preparing the antigen-binding proteins. The application further providespharmaceutical compositions comprising the antigen-binding proteins and methods for treating a disease or disorder using the antigen-binding proteins.

The present invention provides: a culture medium for culturing hematopoietic stem cells in vitro, the culture medium making it possible to selectively culture hematopoietic stem cells when a cell population containing the hematopoietic stem cells and cancer cells is cultured; and a method for culturing hematopoietic stem cells using the culture medium. The present invention relates to: a culture medium for human cells, the culture medium being intended to be used for culturing a cell population containing human cells, and the culture medium comprising a polyalkylene glycol modified by a copolymer of a polyvinylcaprolactam block and a polyvinyl acetate block, a phosphatidylinositol-3 kinase (PI3K) activator, a TPO receptor agonist, and one or more components selected from the group consisting of a proteasome inhibitor, a TNF-related apoptosis-inducing ligand and a cereblon modulator; and a method for culturing human hematopoietic stem cells, the method comprising culturing a cell population containing human hematopoietic stem cells in the aforementioned culture medium for human cells.

The invention relates to the technical field of medicines, and discloses an application of combination of bufalin and heme in preparation of a cancer treatment medicine. According to the invention, by means of an active metabonomics means, a key active metabolite-heme is locked through exogenous library screening and endogenous analysis, and the drug effect of bufalin is regulated by means of the active metabolite. Through verification, it is found that heme can cooperate with the synergistic drug effect in various cancer cell lines, and a new technical normal form based on an active metabolome for improving the drug effect of bufalin is provided. The pharmaceutical composition can improve the apoptosis induction ability of bufalin to different cancer cells, and provides powerful guiding significance for developing a novel treatment scheme in clinical medicine.

The invention belongs to the technical field of medicines, and particularly relates to application of dioscin combined with chidamide in diffuse large B-cell lymphoma. Specifically, research finds that the dioscin can significantly inhibit DLBCL cell proliferation and induce cell cycle arrest and apoptosis by up-regulating PINK1 / Parkin mediated mitochondrial autophagy and enhancing H3K27 acetylation mediated epigenetic regulation. When the chidamide and the dioscin are combined for use, a synergistic effect can be generated, and by further increasing the H3K27ac level, the cell apoptosis induction effect is enhanced, and the in-vivo and in-vitro anti-tumor activity on DLBCL is remarkably improved. The invention provides a novel and efficient DLBCL combined treatment scheme, and provides a new pharmaceutical composition and theoretical support for clinical diagnosis and treatment of DLBCL, so that the application has good practical application value.

The invention relates to application of nobiletin in preparation of an esophageal squamous carcinoma inhibitor. In a cell experiment, nobiletin can inhibit the progress of esophageal squamous carcinoma cells in a plurality of links including growth, invasion inhibition, apoptosis induction and the like. In a tumor-bearing mouse model, nobiletin can effectively inhibit the increase of tumor volume, and has a good anti-cancer effect. Therefore, nobiletin can be used for preparing the medicine for preventing and treating esophageal squamous carcinoma.

The invention discloses an anti-tumor composition containing N-acetyl-D-glucosamine and a preparation method of the anti-tumor composition in the field of anti-tumor preparations. The anti-tumor composition comprises the following components in parts by weight: 1-3 parts of functionalized N-acetyl-D-glucosamine and 3-5 parts of a polypeptide modifier. Through polypeptide modification and application of the N-acetyl-D-glucosamine, the N-acetyl-D-glucosamine (GlcNAc) as a bioactive sugar molecule can possibly have the following effects in tumor microenvironment regulation and control through the immune regulation function of the N-acetyl-D-glucosamine; glycometabolism interference: cancer cells usually grow rapidly depending on the Warburg effect, and the functionalized N-acetyl-D-glucosamine can inhibit proliferation of the cancer cells by influencing the glycometabolism of the cancer cells, and can synergistically play an anti-tumor role in three directions of glycometabolism interference, immunoregulation and cell apoptosis induction.

Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.

The present invention relates to a fusion protein optogenetically activated by blue light, and a use thereof, wherein the fusion protein comprises: an extracellular domain of rhodopsin; a transmembrane domain of rhodopsin; and an intracellular domain of a G-protein coupled estrogen receptor (GPER) bound to the transmembrane domain. Specifically, the invention relates to a fusion protein that is activated by blue light, phosphorylates extracellular signal-regulated kinases (ERKs), inhibits apoptosis, and induces programmed necrosis.

The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.

The invention relates to a stem cell bioactive nano-vesicle with efficient inflammation regulation and tissue repair effects, the average particle size of the nano-vesicle is 100-350nm, the polydispersity index (PDI) is 0.05-0.40, and the expression rate of phosphatidylserine (PS) on the surface of the nano-vesicle is greater than 40%. According to the preparation method, stem cells are subjected to apoptosis induction, and then a programmed serial extrusion process is adopted to prepare the nano-vesicles. The nano vesicles are moderate in particle size, uniform in distribution and high in production efficiency, the preparation process is easy to operate, the quality is stable and controllable, and the nano vesicles have excellent technical effects in the aspects of repair and regeneration of inflammation injury type tissues and organs.

The invention belongs to the technical field of biological pharmacy, and particularly relates to polylysine nanoparticles for delivering oxaliplatin and a preparation method of the polylysine nanoparticles. The invention discloses a preparation method of polylysine nanoparticles for delivering oxaliplatin. The polylysine nanoparticles are applied to preparation of a tumor targeting drug mPssPC-OXA NPs with small particle size, positive surface charge and excellent stability. The mPssPC-OXA NPs can respond to a tumor microenvironment with high GSH concentration to quickly release a drug, and shows an excellent HCT-116 cell uptake effect and an effective RAW264.7 cell immune escape effect in an in-vitro anti-colon cancer cell test. In addition, the mPssPC-OXA NPs also shows more remarkable cytotoxicity, cell migration inhibition, cell proliferation inhibition and HCT-116 cell apoptosis induction effects compared with free OXA.

The invention discloses application of niclosamide in preparation of a medicine for treating endometriosis, and belongs to the technical field of biological medicine. In-vivo and in-vitro experiments prove that the niclosamide can down-regulate the expression of primary endometriosis mesenchymal cells CD47 through a JAK / STAT3 pathway, enhance the phagocytosis of macrophages and play a role in effectively treating endometriosis; the invention provides the preparation method of the niclosamide microneedle, the preparation method is simple, the prepared LPHM-coated DDI NPs shows synergistic cytotoxicity and apoptosis induction activity in endometriosis mesenchymal cells, growth and recurrence of a focus of a subcutaneous endometriosis mouse model can be effectively inhibited through tumor ablation and anti-angiogenesis, and the niclosamide microneedle has a good application prospect. Rapid and effective treatment of endometriosis is realized in a microneedle patch mode.

The invention provides a personalized cancer vaccine based on apoptosis vesicles and a preparation method and application thereof, and belongs to the technical field of biological medicine, the personalized cancer vaccine comprises apoptosis vesicles, an immunologic stimulant and a biocompatibility carrier; the apoptosis vesicles are extracellular vesicles generated after tumor cells are subjected to apoptosis induction; the biocompatible carrier is a modified chitosan hydrogel, and the biocompatible carrier is a modified chitosan hydrogel; the immunologic stimulant is loaded in the apoptosis vesicle, and the apoptosis vesicle loaded with the immunologic stimulant is embedded into the modified chitosan hydrogel. According to the invention, apoptosis vesicles generated by induction of tumor cells of a patient are taken as a core, the apoptosis vesicles have a natural tumor antigen library and a strong immune activation capability, and personalized precise treatment can be realized; meanwhile, the invention provides a preparation method and application in postoperative tumor recurrence prevention and treatment, and provides technical support for clinical transformation.

The present application relates to a method for preparing a dendritic cell for producing a T cell adapter, comprising the steps of: preparing a nucleic acid construct encoding a multispecific T cell adapter comprising a first antigen binding domain and a second binding domain for specifically binding to CD3 on the surface of a T cell to activate the T cell, the second binding domain is an apoptosis inducing ligand TRAIL; and transferring the nucleic acid construct as an exogenous nucleic acid into the DC cell to obtain the dendritic cell for generating the T cell adapter. The dendritic cell for generating the T cell adapter can assist a human immune system in better and more targeted killing of tumor cells.

Provided is a fusion protein comprising a polypeptide component that blocks binding of CD47 to SIRP alpha and a polypeptide that binds to and triggers a TRAIL receptor or Fas. Also provided is a method of treating cancer in a patient comprising administering the fusion protein of the invention to a patient in need of such treatment.

The invention discloses skin mucosa maintenance liquid capable of killing fungi and HPV (human papillomavirus) as well as a preparation method and application of the skin mucosa maintenance liquid, and belongs to the technical field of sterilization and virus removal. The skin mucosa maintenance liquid is prepared from octanol ether, benzalkonium bromide, phenoxyethanol, yermate, parachlorometaxylenol, taetinic acid, chitosan, keratinase, fluconazole, glycerol, borneol, menthol, absolute ethyl alcohol and tween-40. Wherein the skin mucosa maintenance liquid has an effect of regulating apoptosis induction on abnormal cells and an effect on vaginal flora, and has an obvious inhibition effect on cervicitis and colpitis mycotica, namely an anti-inflammatory effect; meanwhile, apoptosis of cells containing HPV16 and HPV18 genes can be induced, shedding of abnormal cells is promoted, diseased cells are killed, and vaginal tissues with pathological changes are removed.

The invention discloses a thiosemicarbazone compound containing a naphthyl structure as well as a preparation method and application of the thiosemicarbazone compound. The thiosemicarbazone compound has biological activity on human breast cancer cells. The anti-tumor activity of the compound is verified through in-vitro experiments, including an inhibition effect experiment of the compound on proliferation of human breast cancer cells, an influence experiment on oxidative stress level of the breast cancer cells, an influence experiment on mitochondrial membrane potential of the breast cancer cells and an experiment for inducing apoptosis of the breast cancer cells. The thiosemicarbazone compound containing the naphthyl structure has remarkable anti-tumor activity, can effectively inhibit proliferation of human breast cancer cells, can remarkably improve the oxidative stress level of the breast cancer cells in a concentration-dependent mode, and has a close correlation between the regulation effect on the mitochondrial membrane potential of the breast cancer cells and the treatment concentration; the compound can effectively induce apoptosis of breast cancer cells, has excellent anti-breast cancer activity, and provides important candidate compounds and theoretical basis for research and development of novel anti-tumor drugs.

The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.

The invention discloses a tumor cell proliferation inhibition physiotherapy device and method based on a specific-intensity micro magnetic field, and belongs to the field of medical instruments.The tumor cell proliferation inhibition physiotherapy device comprises a main board, a rear board is fixed to the rear portion of the upper surface of the main board, a front board is rotatably connected to the front end of the main board, and the left side and the right side of the main board are each provided with two rotating grooves; the universal wheels are arranged at the bottom and matched with a handle of the rear plate, so that flexible pushing can be achieved, the moving direction can be controlled, and transferring is convenient and fast; a folding structure is provided, the support can be driven to retract by turning over the side plates and the front plate, the size of the device is reduced, meanwhile, physiotherapy equipment can be wrapped and protected, losses in the transportation and storage process are reduced, and space is saved; the physiotherapy equipment generates a 1-100mT specific intensity micro magnetic field through current, and cooperates with a warm effect to inhibit tumor cell proliferation from multiple aspects of cell cycle interference, energy metabolism destruction and apoptosis induction, so that the physiotherapy effect is ensured.

The invention discloses an application of brucein D and Vinetoram in preparation of a medicine for treating acute or drug-resistant myelogenous leukemia. Through a large number of experimental screening, the brucein D and the Venotocork are combined for medication, and the test result shows that the brucein D and the Venotocork act on different targets and different signal channels of AML cells to generate a remarkable synergistic anti-tumor effect, and after the brucein D and the Venotocork are combined, the proliferation inhibition and apoptosis induction effects on the AML cells can be directly enhanced, and the anti-tumor effect of the Venotocork D and the AML cells can be improved. The compound can also reverse the drug resistance possibly occurring when the Vinetoram is singly used, and also has a remarkable killing effect on chemotherapy drug-resistant AML cells at the same time. The composition provided by the invention can reduce the dosage of antitumor drugs, reduce drug resistance, reduce adverse reactions and improve the life quality of patients, and has important application prospects.

The invention relates to stem cell-derived engineered nano-vesicles (e-NVs) for promoting hair growth, the engineered nano-vesicles are prepared from stem cells through engineering induction, apoptosis induction and programmed serial extrusion processes in sequence, and an inducer used for engineering induction is 3, 3 '-diindolylmethane. The particle size of the engineered nano vesicle is mainly distributed in a range of 50-300 nm, the polydispersity coefficient is 0.05-0.20, and the expression proportion of phosphatidylserine is 40%-50%. The rice vesicles can effectively improve the hair follicle microenvironment, adjust the hair growth cycle, promote proliferation and differentiation of hair follicle stem cells and remarkably increase the hair regeneration rate of androgenetic alopecia model mice, and a safe, convenient and efficient clinical strategy is provided for hair regeneration treatment.

This invention relates to the field of biomedical technology, and more particularly to a method for preparing mesenchymal stem cell apoptotic vesicles. The method primarily employs serum-free culture medium for 3D microsphere culture of stem cells, followed by induction of apoptosis into apoptotic vesicles using an apoptosis induction system, resulting in highly efficient apoptotic vesicles. This method significantly enhances the bidirectional immunomodulatory effect of stem cell-derived apoptotic vesicles, greatly expanding the application range and therapeutic efficacy of these vesicles. The serum-free culture medium avoids the safety risks and batch-to-batch variations associated with traditional culture media, and significantly improves the proliferation capacity, passage stability, and immunomodulatory effect of stem cells, enabling stable and efficient acquisition of apoptotic vesicles.